Skip to main content
MyPeptideMatch
The Journal

Peptide Therapy Insights

Evidence-based guides, regulatory updates, and expert perspectives on peptide therapy. Stay informed with the latest research and clinical insights.

FDA's Crackdown on Compounded GLP-1 Drugs: What Patients Need to Know in 2026
Regulatory

FDA's Crackdown on Compounded GLP-1 Drugs: What Patients Need to Know in 2026

The FDA removed semaglutide and tirzepatide from its drug shortage list in early 2025, ending the compounding exemption that had allowed hundreds of pharmacies to produce GLP-1 copies at lower cost. Here's what that means for your access, your wallet, and your options right now.

Read Article

More in Regulatory

Stay Up to Date

New articles on peptide therapy, FDA regulations, and clinic reviews are published regularly. Bookmark this page or check back often.